COVID-19疫情期间前列腺癌择期诊疗的多学科团队经验
该研究比较了意大利某医院多学科团队在COVID-19疫情高峰月份(2020年3月)与非疫情月份(2019年3月)对前列腺癌择期诊断和治疗流程的差异。结果显示,除晚期激素敏感或去势抵抗性前列腺癌的药物治疗未显著减少外,其他管理均显著减少。作者描述了疫情下不可推迟的择期前列腺癌管理建议,并强调应根据疫情和医院参与程度调整指征。
要点
- 疫情高峰月择期前列腺癌诊疗量除晚期药物治疗外均显著下降。
- 多学科团队需识别不可推迟的择期前列腺癌管理。
- 建议应根据疫情严重程度和医院COVID-19收治情况动态调整。
核心结论
- 在COVID-19疫情期间,前列腺癌择期诊疗除晚期激素敏感或去势抵抗性前列腺癌的药物治疗外均显著减少。
- 多学科团队应识别不可推迟的择期前列腺癌管理,并根据疫情和医院参与程度调整指征。
研究设计与样本
- 回顾性比较研究,比较同一多学科团队在2020年3月(COVID-19高流行且全国限制期间)与2019年3月(无COVID-19月份)的前列腺癌择期诊断和治疗操作。
主要发现
- 唯一未显著减少的管理是晚期激素敏感或去势抵抗性前列腺癌的药物治疗。
- 其他择期诊断和治疗操作均显著减少。
临床怎么用
- 在COVID-19疫情期间,多学科团队应优先保障不可推迟的前列腺癌管理,尤其是晚期激素敏感或去势抵抗性前列腺癌的药物治疗。
- 择期诊疗指征应根据当地疫情严重程度和医院COVID-19收治情况动态调整,必要时仅限急诊。
局限性
- 建议基于意大利一个地区的数据,该地区实际疫情影响较低且医院未完全转为COVID-19管理,外推需谨慎。
- 指征应随疫情和医院参与程度变化而调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
On March 29th 2020, 97,689 cases of COVID-19 have been diagnosed only in Italy, with 73,880 actually positive cases, a daily increase of 3815 cases, 27,386 hospitalized and 3906 patients in intensive care units, causing a total of 10,779 known deaths. In all urological departments, quickly inpatient and outpatient services have been significantly reduced. Even in this COVID-19 situation, urological neoplasm care must go on, but significant changes need to be made in the way some care is delivered. We compared diagnostic and therapeutic elective procedures requested and performed for PC management from our multidisciplinary team (MDT) during 1 month activity in the highest national level of COVID-19 infection (March 2020) and under restrictions for all the population, with the management performed in a no-COVID-19 month (March 2019) 1 year ago. The only management that did not received a significant reduction are medical therapies for advanced hormone sensitive (HS) or castration resistant (CR) PC. We describe our MDT identifications of elective undeferrable PC management in this COVID-19 time. These suggestions have been considered for a country (ITALY) under a rapid increase of COVID-19 cases and complications, but in a region with an actual lower impact (2914 actual positive and 1079 hospitalized cases) from the infection and in an hospital not completely converted to COVID-19 management. Indications should be different and restricted only to emergencies on the basis of COVID-19 pandemic situation and hospital involvement.
引用
- Sciarra A, Salciccia S, Maggi M, et al. Elective procedures for prostate cancer in the time of Covid-19: a multidisciplinary team experience. Prostate Cancer Prostatic Dis. 2020. PMID: 32425655. doi:10.1038/s41391-020-0240-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。